The effect of antiracetam (AN), a nootropic drug, which is one of the modulators of glutamate receptors of the AMPA type, in relation to amphetamine effects on locomotor activity as well as on the content of noradrenalin, dopamine, serotonin, and their metabolites in frontal cortex, hippocampus, hypothalamus, and striatum, was studied in C57/bl mice. AN, at a intraperitoneal dosage of 100 mg/kg, moderately decreased the locomotor activity of mice in comparison with the control. AN in combination with amphetamine did not significantly change the psychostimulating effect of the latter. The content of monoamines and their metabolites in the brain was not considerably changed after AN introduction. However, amphetamine-induced reduction of homovanillic acid and 5-hydroxyindolacetic acid in the brain was weakened by AN administration. It is proposed that the glutamate-dopaminergic intermediator interaction may be involved in the effect of AN.